Bi-Functional Topospecific Nanoparticles to Promote Immune-Tumor Cell Engagement as A New Immunotherapeutic Strategy
© 2025 The Author(s). Advanced Materials published by Wiley‐VCH GmbH.
| Veröffentlicht in: | Advanced materials (Deerfield Beach, Fla.). - 1998. - (2025) vom: 24. Sept., Seite e18838 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2025
|
| Zugriff auf das übergeordnete Werk: | Advanced materials (Deerfield Beach, Fla.) |
| Schlagworte: | Journal Article PD‐1 communication immunotherapy nanoparticles pHLIP |
| Zusammenfassung: | © 2025 The Author(s). Advanced Materials published by Wiley‐VCH GmbH. Cancer immunotherapy has emerged as a promising alternative approach, enabling the body's immune system to fight cancer. Cytotoxic T cells play a pivotal role in recognizing and eliminating tumor cells, and their effectiveness relies on establishing a physical interaction and efficient communication with cancer cells. However, this communication is often disrupted by immune escape mechanisms, allowing cancer progression. A versatile nanoplatform is developed to restore cellular connection using Janus mesoporous silica-Au nanoparticle (J-pHLIP-PD1), including specific binding sites on opposite faces for simultaneous binding to cancer cells and immune cells. The two differential surfaces on the nanoparticle allow orthogonal functionalization with the anti-PD-1 antibody that interacts with the PD-1 receptor in cytotoxic T cells on the gold face and the pH Low Insertion Peptide (pHLIP), which undergoes specific insertion into the tumor cell membrane on the silica face. J-pHLIP-PD1 nanoparticles effectively bind the surface of tumor cells and capture T cells, facilitating the formation of immune synapse-like structures that lead to reduced cancer cell viability in vitro, associated with immunogenic cell death signatures. The therapeutic potential of J-pHLIP-PD1 is also demonstrated in an in vivo metastatic melanoma model, where treatment with J-pHLIP-PD1 produces a significant decrease in metastatic burden and increases T cell presence. The Janus nanosystem represents an attractive platform that expands the toolbox of immune-engaging strategies, offering a flexible alternative to conventional immunotherapies that link immune and tumor cells, restoring cell-cell communication for cancer elimination |
|---|---|
| Beschreibung: | Date Revised 24.09.2025 published: Print-Electronic Citation Status Publisher |
| ISSN: | 1521-4095 |
| DOI: | 10.1002/adma.202418838 |